RA Capital Management Increases Stake in Artiva Biotherapeutics

RA Capital Management, L.P. increased its stake in Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) by purchasing 15,414 shares on June 15, 2026. The shares were bought at an average price of $8.99, amounting to a total value of $138,571.86. This move is part of a series of recent transactions by RA Capital Management, which has been actively buying shares of Artiva throughout June.

Other Institutional Activity in Artiva Biotherapeutics

RA Capital Management holds a substantial position in Artiva Biotherapeutics, with 9,853,302 shares valued at approximately $63.5 million. Other funds, such as 5AM Venture Management and Venrock Adviser, have maintained their positions with 2,353,304 shares worth about $15.2 million and 1,609,569 shares valued at $10.4 million, respectively. Venbio Partners LLC trimmed its holdings by 117,170 shares, now holding 531,337 shares valued at $3.4 million.

Artiva Biotherapeutics Stock Snapshot

Shares of Artiva Biotherapeutics traded near $9.18 on the NasdaqGM. The company has a market capitalization of around $414.9 million. Artiva's forward P/E ratio isn't meaningful as the company isn't currently profitable. The stock's 52-week range is between $1.47 and $14.53, with a 50-day moving average of $9.04 and a 200-day moving average of $5.33. Artiva has a current ratio of 8.16 and a quick ratio of 7.98, indicating strong liquidity.

Insider Buying and Selling at Artiva Biotherapeutics, Inc.

RA Capital Management has been actively buying shares of Artiva Biotherapeutics. On June 16, 2026, they purchased 124,893 shares at an average price of $8.89. Earlier transactions include buying 391,019 shares at $8.57 on June 12, and 548,580 shares at $7.91 on June 11. These purchases were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 8, 2026, Needham reiterated its buy rating for Artiva Biotherapeutics with a price target of $41. Cantor Fitzgerald and Wedbush also maintained their buy ratings with $40 targets in May 2026. Analysts have a consensus strong buy rating on Artiva, with a mean price target of $35.8 based on five opinions.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., headquartered in San Diego, California, is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. These therapies aim to treat autoimmune diseases and cancers. Their lead product, AlloNK, targets conditions like rheumatoid arthritis and various cancers, while other products in development target solid tumors and hematological malignancies. Founded in 2019, the company is led by CEO Dr. Fred Aslan.

Bottom Line

RA Capital Management's continued investment in Artiva Biotherapeutics reflects its confidence in the company's potential. Artiva is actively developing innovative therapies in the biotechnology sector, making it a closely watched stock. Investors should note that insider buying doesn't always predict future stock performance, and these transactions offer a backward-looking view of RA Capital's recent activity.